

Press Release

Zofingen, December 7, 2011

Siegfried was presented with Novartis' "Global Supplier Award" for 2011

Novartis, the Swiss pharmaceutical company, bestowed the 2011 "Global Supplier Award" on Siegfried. The award is presented annually to only two suppliers.

Under the motto "Value creation through innovation", Siegfried has made a decisive contribution toward the market success of a drug currently on sale in the USA. The process development for the active pharmaceutical ingredient (API) was carried out in Siegfried's Pennsville (USA) plant where it is also being produced. The project is exemplary for Siegfried's cooperation with customers in the pharmaceutical industry. The development of a demanding API takes several years and requires careful coordination among various areas of expertise in the field of process chemistry. The areas of expertise include analytical, scale-up to industrial quantities, and production with a high awareness for quality.

Marianne Späne, Siegfried's Head of Business Development & Sales: "The aim of a successful supplier-customer model is to grow a business idea into a cooperation based on partnership that will lead to a successful strategic alliance. For us, the Novartis Supplier Award is proof that Siegfried is on the right track and is one of the world's leading suppliers."

For further information:

Peter Gehler, Head Corporate Center

peter.gehler@siegfried.ch

Tel. +41 (0)62 746 11 48

Mobile +41 (079) 416 41 16

Fax +41 (0)62 746 11 03

Siegfried Holding AG

Untere Brühlstrasse 4

CH-4800 Zofingen

Tel. +41 (0)62 746 11 11

Fax +41 (0)62 746 11 03

www.siegfried.ch

About Siegfried

Active in Life Science markets, the Siegfried Group is a global manufacturer of pharmaceutical products with production facilities located in Switzerland, Malta and the USA. At the end of 2010, Siegfried employed approximately 700 employees and achieved annual sales of CHF 314 million. Siegfried Holding AG is listed on the Swiss Exchange in Zurich (SIX: SFZN).

Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and standard products, and provides development and production services for drugs in finished dosage forms.